Hanall Biopharma Rises 5.37% Amid Immune Oncology Theme Uptrend

On the 19th, the immuno-oncology theme showed strength with a 4.29% increase compared to the previous day, while HanAll Biopharma, gaining attention as a related stock, surged by 5.37%. HanAll Biopharma is known as an R&D-focused pharmaceutical and bio company.

[Graph] Price Fluctuations of Major Stocks in the Immuno-Oncology Theme

According to provisional data compiled at 14:03, foreign investors have been making large net purchases, acquiring 52,600 shares of HanAll Biopharma.

[Table] Net Purchases by Foreign and Institutional Investors (Unit: 10,000 shares)

According to the analysis by Thinkpool Robo Algorithm RASSI, HanAll Biopharma ranked 3rd out of 26 stocks in the quant financial ranking by exceeding the theme’s average scores in growth, stability, and profitability. This can be interpreted as HanAll Biopharma having relatively high investment attractiveness compared to other stocks within the theme from a financial perspective.

[Table] Top Stocks by Financial Scores within the Theme

※ The quant financial scores are results analyzed by the Robo Algorithm based on each company’s sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, and other factors.

※ This article was generated in real-time by an automated article creation algorithm jointly developed by Asia Economy and the financial AI specialist Thinkpool.

This content was produced with the assistance of AI translation services.